The combination of the p38 MAPK inhibitor ARRY-614 plus nivolumab with or without ipilimumab was well…
Tag: inhibition
FY2022 EPS Estimates for Inhibrx, Inc. Raised by Jefferies Financial Group (NASDAQ:INBX)
Inhibrx, Inc. (NASDAQ:INBX – Get Rating) – Equity analysts at Jefferies Financial Group have raised their…
Inhibrx (NASDAQ:INBX) Price Target Cut to $46.00 by Analysts at Credit Suisse Group
Inhibrx (NASDAQ:INBX – Get Rating) had slashed its price target from analysts at Credit Suisse Group…
Inhibrx (NASDAQ:INBX) Shares Down 7.4% After Insider Selling
Shares of Inhibrx, Inc. (NASDAQ:INBX – Get Rating) fell 7.4% on Thursday afternoon on insider selling…
Inhibrx (NASDAQ:INBX) Price Target Raised to $60.00
Inhibrx (NASDAQ:INBX – Get Rating) The target price was raised from $54.00 to $60.00 by equity…
